uniQure N.V. (QURE) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed uniQure N.V. (QURE) over the past year, losing 4.7% versus a loss of 30.4%. Over five years, TYRA leads with a -15.7% price change compared with -32.9% for QURE. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | TYRA |
|---|---|---|
| Share price | $19.35 | $20.12 |
| Market cap | $1.36B | $1.39B |
| 1-day change | -4.35% | +1.98% |
| YTD return | -19.14% | -23.47% |
| 1-year return | -30.42% | -4.73% |
| 5-year return | -32.86% | -15.71% |
| EPS (TTM) | $-3.51 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.10M | — |
| Revenue growth (YoY) | -40.64% | — |
| Net income (latest FY) | $-198.97M | $-119.95M |
| Gross margin | 89.53% | — |
| Operating margin | -1151.38% | — |
| Net margin | -1236.00% | — |
| 52-week high | $51.72 | $40.65 |
| 52-week low | $8.73 | $18.25 |
| Distance from 52-week high | -62.59% | -50.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +207.03% | +135.83% |
| Average volume | 2.26M | 852.56K |
| Shares outstanding | 70.14M | 69.08M |
| Employees | 221 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed QURE by 25.7 percentage points over the past year.
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
QURE vs TYRA FAQ
Which is bigger, uniQure N.V. or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.36B for uniQure N.V. (QURE).
Which stock has performed better over the past year, QURE or TYRA?
TYRA returned -4.73% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.